Investing Profile

Ken Belotsky

Founding Partner at Negev Capital. Leading VC in psychedelic drug development

negevcap.comTel Aviv, Israel

Your Intro Paths to Ken Belotsky

Signal uses Gmail to reveal intro paths. Email content is never read.

Find Ken Belotsky on

Current Investing Position

Negev Capital Managing Partner

Investment Range

$500K - $3.0M

Sweet Spot

$1M

Investments On Record

Ken Belotsky is on these Sector & Stage Rankings

Ken Belotsky's Investments On Record (6)

Company	StageDateRound Size	Total Raised
Gilgamesh Pharmaceuticals	series BMay 2022$1	$68M
Co-investors: Eric Brook (B Capital Group), Kunal Sethi (Prithvi Ventures), Amy Kruse (Prime Movers Lab), Dave Messina (Pioneer Fund), Stephen Hays (What If Ventures), Martin Tobias (Incisive Ventures), Lucas Vaz (Ravelin Capital), Rand Hindi
Mindstate Design Labs	Seed RoundFeb 2022$12M	$24M
Co-investors: Fred Ehrsam (Paradigm), Eric Brook (B Capital Group), Kunal Sethi (Prithvi Ventures), Naval Ravikant (The Hit Forge), Rand Hindi
Delix Therapeutics	Series ASep 2021$70M	$70M
Co-investors: Andrew Levin (RA Capital), Matias Serebrinsky (PsyMed Ventures), Vasudev Bailey (Artis Ventures (AV))
Beckley Psytech	Series BAug 2021£58M	$80M £58M
Co-investors: Eric Brook (B Capital Group), Kunal Sethi (Prithvi Ventures), Amy Kruse (Prime Movers Lab), Matias Serebrinsky (PsyMed Ventures), Stephen Hays (What If Ventures)
ATAI Life Sciences	Series BMar 2019$43M	$220M
Co-investors: Stephen Hays (What If Ventures), Matias Serebrinsky (PsyMed Ventures), Martin Alexander Gershon (Endeavor Venture Funds), Maryanna Saenko (Future Ventures), Akshay Sriprasad
Small Pharma	Seed RoundApr 2017£830K	$1M £830K
Co-investors: Peter Keen, David Ebsworth